Scholar Rock Total Liab Over Time
SRRK Stock | USD 26.67 1.19 4.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Scholar Rock Performance and Scholar Rock Correlation. Scholar |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scholar Rock. If investors know Scholar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scholar Rock listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.36) | Quarterly Revenue Growth (1.00) | Return On Assets (0.67) | Return On Equity (1.83) |
The market value of Scholar Rock Holding is measured differently than its book value, which is the value of Scholar that is recorded on the company's balance sheet. Investors also form their own opinion of Scholar Rock's value that differs from its market value or its book value, called intrinsic value, which is Scholar Rock's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scholar Rock's market value can be influenced by many factors that don't directly affect Scholar Rock's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scholar Rock's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scholar Rock is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scholar Rock's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare Scholar Rock Holding and related stocks such as Tcr2 Therapeutics, Revolution Medicines, and Black Diamond Therap Total Liab Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RVMD | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 73.9 M | 68 M | 92.7 M | 135.4 M | 126.7 M | 235.5 M | 247.3 M |
BDTX | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 67.4 M | 209.3 M | 21.9 M | 491.5 M | 40.6 M | 41.8 M | 39.7 M |
PASG | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 4.3 M | 23.3 M | 36.4 M | 42.2 M | 39.3 M | 35 M |
GLUE | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 98.1 M | 18.8 M | 71 M | 124.5 M | 73.8 M |
DSGN | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 47.8 M | 8.4 M | 13.8 M | 12 M | 13.7 M |
HOWL | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 148.3 M | 26.5 M | 37.9 M | 63.5 M | 51.5 M |
IKNA | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 269.5 M | 40 M | 25.3 M | 22.3 M | 21.2 M |
STOK | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 2.5 M | 4.3 M | 11.8 M | 21.1 M | 71.2 M | 68.8 M | 72.2 M |
IDYA | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 145.5 M | 113 M | 298.3 M | 381.3 M | 388 M | 28.2 M | 26.8 M |
ANAB | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 19.1 M | 13.9 M | 22.9 M | 21.8 M | 22.6 M | 30.2 M | 19.8 M | 286.6 M | 348.3 M | 364.3 M | 382.5 M |
MGTX | 39.7 M | 39.7 M | 39.7 M | 39.7 M | 39.7 M | 39.7 M | 39.7 M | 73.2 M | 15.8 M | 133.1 M | 125.1 M | 134.8 M | 200.5 M | 188.6 M | 125.2 M |
KROS | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 5.5 M | 7.7 M | 12.1 M | 29.4 M | 37.8 M | 19.6 M |
RNA | 29.3 M | 29.3 M | 41.9 M | 38 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 162.3 M | 27.7 M | 46.1 M | 60.7 M | 127.8 M | 70.7 M |
IGMS | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 69.8 M | 21.1 M | 26.8 M | 53.2 M | 226.2 M | 220.2 M | 231.2 M |
CGEM | 323 K | 323 K | 323 K | 1 M | 1.2 M | 1.2 M | 578.3 K | 55.3 M | 55.3 M | 140.4 M | 291 M | 11.8 M | 26.1 M | 30.3 M | 55.9 M |
MLYS | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 34 M | 166.7 M | 10.5 M | 10 M |
RLAY | 539.5 M | 539.5 M | 539.5 M | 539.5 M | 539.5 M | 539.5 M | 539.5 M | 539.5 M | 539.5 M | 573.5 M | 36.5 M | 110.6 M | 149.6 M | 92 M | 87.4 M |
PLRX | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 67.4 M | 119.5 M | 12.5 M | 22.2 M | 37.3 M | 38.6 M | 34.4 M |
ARVN | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 66.6 M | 62.6 M | 75 M | 75.1 M | 799.9 M | 703.9 M | 644.6 M | 335.7 M |
Scholar Rock Holding and related stocks such as Tcr2 Therapeutics, Revolution Medicines, and Black Diamond Therap Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
Scholar Rock Holding | SRRK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | Massachusetts; U.S.A |
Exchange | NASDAQ Exchange |
USD 26.67
Check out Scholar Rock Performance and Scholar Rock Correlation. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Scholar Rock technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.